Summary
F. Hoffmann-La Roche Ltd (Roche) develops drugs that improve the standard of care across major disease areas. It provides pharmaceuticals in cancer, neuroscience, infection, immunology, ophthalmology, cardiovascular and metabolism, immunology, hematology, hemophilia and respiratory disease areas. The company also provides in vitro diagnostics, tissue-based cancer diagnostics, as well as diabetes management solutions. Roche’s diagnostic products include clinical chemistry and immunoassays, molecular diagnostics, tissue diagnostics, point of care diagnostics, laboratory automation and IT solutions, urinalysis products, lab testing products, custom biotech solutions, patient self-testing products and solutions for life science. The company offers its products and services to hospitals, commercial diagnostic laboratories, healthcare professionals, researchers and pharmacists. Roche is headquartered in Basel, Switzerland.
F. Hoffmann-La Roche Ltd (ROG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 11
List of Figures 18
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 19
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 20
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 21
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 22
F. Hoffmann-La Roche Ltd, Medical Devices Deals, 2011 to YTD 2017 24
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 25
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deal Details 51
Asset Purchase 51
Roche to Acquire Heat Elution Purification Technology from Lumora 51
Roche Acquires PETE Technology from AbVitro 51
Genentech Acquires NanoPrint LM60 Microarrayer Platform From Arrayit 52
Roche To Acquire Gene Sequencing Technologies From Three Universities 53
Venture Financing 54
SutroVax Raises USD64 Million in Series B Financing 54
Tioma Therapeutics Raises USD86 Million in Series A Financing 55
Second Genome Raises USD8.4 Million in Extended Series B Financing 56
Second Genome Raises USD42.6 Million in Series B Financing 57
Lumos Pharma Raises USD34 Million in Series B Financing Round 59
Mission Therapeutics Raises USD85.7 Million in Financing Round 60
Biodesy Raises USD10 Million in Series B Financing 62
C4 Therapeutics Raises USD73 Million in Series A Financing Round 63
Millendo Therapeutics Raises USD62 Million in Series B Venture Financing 64
Minoryx Therapeutics Raises USD22 Million in Series A Financing Round 65
Corvus Pharma Raises USD75 Million in Series B Venture Financing 67
AveXis Raises USD65 Million in Venture Financing 68
SutroVax Raises USD22 Million in Series A Venture Financing 70
Stratos Genomics Raises Additional USD15 Million in Series B Financing 71
Allakos Secures USD27.95 Million in Venture Funding 72
Macrolide Pharma Raises USD22 Million in Series A Financing 73
Lysosomal Therapeutics Raises USD20 Million in Series A Financing 74
AveXis Raises USD10 Million in Series C Financing Round 75
CytomX Therapeutics Raises USD20 Million in Series C Venture Financing 76
Curetis Raises USD18 Million in Extended Series B Venture Financing 77
Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 79
Allakos Raises USD10 Million in Extended Series A Venture Financing 81
Epic Sciences Raises USD30 Million in Series C Venture Financing 82
Lysosomal Therapeutics Raises US$4.8 Million In Seed Financing 83
Alios BioPharma Raises US$41 Million In Series B Venture Financing 85
Eloxx Pharma Raises Funds Through Initial Tranche Of First Round Of Financing 86
Aileron Therapeutics Raises US$30 Million In Series E Financing 87
Mission Therapeutics Raises US$32 Million In Series B Financing 88
Biodesy Raises US$15 Million In Series A Financing 90
Seragon Raises US$30 Million In Series A Financing 91
Opsona Therapeutics Raises USD46.8 Million In Extended Series C Financing 92
Horizon Discovery Raises US$10.5 Million In Final Closing Of Series C Financing 94
Aileron Raises US$12 Million In Extended Series D Financing 96
Foundation Medicine Raises US$56 Million In Series B Financing 97
Allakos Raises US$32 Million In Series A Financing 100
Epic Sciences Raises US$13 Million In Series B Financing 101
Ambit Biosciences Raises US$25 Million In First Tranche Of Venture Financing 102
cCAM Biotherapeutics Raises US$6 Million In Series A Financing 104
Cytomx Therapeutics Raises Additional US$11 Million In Series B Financing 105
Santaris Pharma Raises US$12 Million In Venture Financing 106
GeneWeave Raises US$12 Million In Series A Financing Round 108
Foundation Medicine Secures Additional US$8.5 Million In Series A Venture Financing 109
Horizon Discovery Raises US$17.9 Million In Series C Financing 110
Tensha Therapeutics Secures US$15 Million In Series A Venture Financing 111
Mission Therapeutics Raises US$10 Million In Series A Financing 112
Foundation Medicine Raises US$10 Million In Venture Financing 113
Ambit Biosciences Secures US$30 Million In Series D-2 Financing 114
Conatus Pharma Secures US$7.5 Million In Second Closing Of Series B Preferred Stock 116
Partnerships 118
Helsinn Enters into Licensing Agreement with Chugai Pharma for Netupitant-Palonosetron Fixed-Dose Combination 118
Bavarian Nordic Enters into Agreement with Roche 118
Exelixis Enters into Agreement with Roche 119
Amunix Operating Enters into R&D Agreement with Genentech 120
Gradalis Enters into Agreement with Genentech 121
G1 Therapeutics Enters into Agreement with Genentech 122
F. Hoffmann-La Roche Expands its Distribution Agreement with MilliporeSigma 123
Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 123
Charles River Laboratories International Extends Agreement with Genentech 124
Epizyme Enters into Agreement with Foundation Medicine 125
BioNTech to Enter into Agreement with Genentech 126
BioLineRx Enters into Agreement with Genentech 127
Epizyme Enters into Agreement with Genentech 128
Foundation Medicine Enters into Agreement with AstraZeneca 128
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 129
Chugai Pharmaceutical Enters into Agreement with Osaka University 131
Foundation Medicine Partners with AstraZeneca 132
Astex Pharma to Form Partnership with Genentech 133
Clovis Oncology Enters into Agreement with Genentech 134
Janssen Research & Development Enters into Agreement with Genentech 134
Kite Pharma Enters into Agreement with Genentech 135
Eli Lilly Enters into Agreement with Roche Diagnostics International 136
Lead Discovery Center to Enter into Drug Discovery Agreement with Roche 137
F. Hoffmann-La Roche Enters into Research Agreement with Catalent 138
Genticel Enters into Agreement with Roche Molecular Systems 138
C4 Therapeutics Enters into Partnership with Roche Pharma 139
Flatiron Health to Enter into Agreement with F. Hoffmann-La Roche 140
Foundation Medicine Enters into Agreement with Mirati Therapeutics 141
PeptiDream Enters into Agreement with Genentech 141
Roche Enters into Agreement with SQZ Biotech 142
DexTech Medical Enters into Research Agreement with Roche 143
Roche Extends Agreement with Amunix for XTEN technology 144
Corvus Pharma Enters into Agreement with Genentech 145
Roche Enters into Agreement with National Institute for Public Health and the Environment 145
Janus Biotherapeutics Enters into Agreement with Roche 146
Immune Design Enters into Clinical Trial Collaboration with Genentech 147
WaferGen Bio-systems Enters into Research Agreement with Genentech 147
Bina Technologies Enters into Agreement with AstraZeneca 148
Ventana Medical Enters into Agreement with Astellas Pharma to Develop Novel Automated Tissue Diagnostics 149
Roche Plans to Enter into Agreement for Immuno-Oncology Therapies 150
Sigma-Aldrich Enters into Distribution Agreement with Roche 150
Celldex Therapeutics Enters into Agreement with Roche 151
Roche Enters into Development Agreement with BioMed X 152
Foundation Medicine Enters into Co-Development Agreement with H3 Biomedicine 152
Roche Enters into R&D Agreement with Foundation Medicine 153
23andMe Partners with Genentech 154
Foundation Medicine Enters into Co-Development Agreement with Flatiron Health 155
Molecular Devices Enters into Co-Development Agreement with Roche Diagnostics 156
Ventana Medical Systems Enters into Co-Development Agreement with ImmunoGen 156
Cardiorentis Enters into Co-Development Agreement with Roche for Ularitide 157
Pharmathen Pharma Enters into Co-Marketing Agreement with InterMune 158
Roche NimbleGen Enters into Co-Development Agreement with Garvan Institute of Medical Research 159
Roche Enters into Agreement with AmorChem to Develop Myotonic Dystrophy Treatment 159
AstraZeneca Enters into Co-Development Agreement with Roche 160
Advanced Biological Labs Extends Co-Promotion Agreement with Roche Diagnostics 161
Bioprocessing Tech Institute Enters Into Agreement with Roche to Develop Cancer Therapeutics 162
Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 162
Roche Enters into Co-Development Agreement with Stratos Genomics 163
AUT University Forms Joint Venture with Roche Diagnostics 164
Ferring Pharma Enters into Co-Development Agreement with Roche 164
Roche to Form Joint Venture with Inception Sciences and Versant Ventures 165
Bind Therapeutics Enters into Research Agreement with Roche for Accurins 166
Foundation Medicine Enters Into Distribution Agreement With Laboratorios Leti 167
PGI Drug Discovery And Roche Expand Drug Discovery Agreement 168
Spero Therapeutics Enters into Co-Development Agreement with Roche for Drug-Resistant Bacterial Infections 169
Roche Holding Expands Co-Development Agreement with Oryzon Genomics 169
Ventana Medical Systems Enters Into Co-Development Agreement With Genmab 170
Roche Enters Into Research Agreement With Laval University 171
Santaris Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For RNA-Targeted Medicines 172
Santaris Enters Into Co-Development Agreement With Roche For RNA-Targeted Drugs 173
Foundation Medicine Expands Co-Development Agreement With Novartis 174
Pierre Fabre Enters into Agreement with Roche for NeoRecormon 175
immatics Enters Into R&D Agreement With Roche For Cancer Vaccine 175
Argenta Discovery Extends Drug Discovery Agreement With Genentech 177
Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology 178
Advanced Biological Labs And Roche Diagnostics Enter Into Agreement To Promote Sequencing, Genotyping And Drug Resistance Products 179
Shire Extends Research Agreement With Santaris Pharma For LNA Drugs 180
AstraZeneca, Roche And MedChemica Enter Into Agreement To Accelerate Drug Development 180
Macrocyclics Enters Into Co-Development Agreement With Roche For Chelating Agents 181
Santaris Pharma Enters Into Agreement With Bristol-Myers Squibb For RNA-Targeted Medicines 182
Roche Enters Into Agreement With Ascletis To Develop HCV Drug Danoprevir 183
Roche Enters Into Co-Development Agreement With Isis Pharma For Huntington's Disease Treatment 184
Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 185
Roche Enters Into Co-Development Agreement With BioLamina For Cell Culture Systems 186
Roche Enters Into Technology Transfer Agreement With Emcure Pharma For Two Patented Cancer Drugs 187
RQx Pharma Enters Into Drug Discovery Agreement With Genentech 188
ProMining Therapeutics Enters Into Agreement With Roche To Discover Small Molecule Therapeutics 189
Redbiotec Enters Into Co-Development Agreement With Roche Diagnostics 190
Chugai Pharma Enters Into Co-Development Agreement With Nippon Shinyaku For GA101 190
Foundation Medicine Enters Into Agreement With AstraZeneca For Genomic Profiling 192
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 192
Roche Enters Into Co-Development Agreement With Areva Med 193
Handok Enters Into Co-Marketing Agreement With Roche For Madopar 194
Ensemble Therapeutics Enters Into Drug Discovery Agreement With Genentech 195
Roche, ANRS, Baylor Researh Institute And Inserm Transfert Enter Into Co-Development Agreement For Therapeutic Vaccines 196
Chong Kun Dang Pharma Enters Into Co-Marketing Agreement With Roche For Six Products 197
Constellation Pharma Enters Into Co-Development Agreement With Genentech 198
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 199
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 200
Ventana Medical Systems Enters Into Co-Promotion Agreement With Advanced Cell Diagnostics 201
Roche Enters Into Joint Venture Agreement With Swiss Federal Institute of Technology, University of Zurich And University Hospital Zurich 202
Galena Biopharma Enters Into Co-Development Agreement With The Henry M. Jackson Foundation And Genentech 203
Roche Expands Co-Development Agreement With Aileron Therapeutics 204
BioBay Enters Into Co-Development Agreement With Roche And Harvard University 205
The Centre For Drug Research Enters Into Co-Development Agreement With F. Hoffmann-La Roche 206
Uppsala BIO Enters Into Co-Development Agreement With F. Hoffmann-La Roche 207
Evotec Enters Into Co-Development Agreement With Roche 208
Argenta Discovery Extends Drug Discovery Agreement With Genentech 209
Array BioPharma Enters Into Co-Development Agreement With Genentech 210
Schnell BioPharma Enters Into Co-Development Agreement With Aprogen And Chunggei Pharm 211
Merck Extends Co-Promotion Agreement With Roche For VICTRELIS 212
Roche NimbleGen Enters Into Co-Marketing Agreement With Caliper Life Sciences 213
F. Hoffmann-La Roche Enters Into Co-Development Agreement With CPRIT 214
F. Hoffmann-La Roche Enters Into Co-Development Agreement With UCLA's Jonsson Comprehensive 215
Roche Enters Into Co-Development Agreement With Clovis Oncology 216
Hoffmann-La Roche Enters Into Co-Development Agreement With Bristol-Myers Squibb 217
Roche Applied Science Enters Into Co-Marketing Agreement With IT-IS Life Sciences 218
Roche Diagnostics Enters Into Research Agreement With Vall d’Hebron Institute, CIBE-Rehd And Advanced Biological Labs 218
Invida Group Enters Into Agreement With F. Hoffmann-La Roche 220
Plexxikon Enters Into Co-Promotion Agreement With Genentech 221
Santaris Pharma Expands Its Collaboration With Pfizer 222
RAD BioMed Forms Joint Venture With Pontifax And Roche 223
Licensing Agreements 224
Mylan Enters into Licensing Agreement with Genentech and Roche 224
Chugai Pharma Enters into Licensing Agreement with SBI Pharma 225
CiVi Biopharma Enters into Licensing Agreement with F. Hoffmann-La Roche 225
Chugai Pharma Enters into Licensing Agreement with Pharma Mar 226
Roche Enters into Licensing Agreement with ImmuNext 227
Genentech Enters into Licensing Agreement with Novimmune 228
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 229
Genentech to Enter into Licensing Agreement with Hanmi Pharma 229
Phylogica Extends Licensing Agreement with Genentech 230
Roche Expands its Licensing Agreement with Discuva 232
Novogen Enters into Licensing Agreement with Genentech for GDC-0084 232
Maruho Enters into Licensing Agreement with Chugai Pharma 233
Denali Therapeutics Enters into Licensing Agreement with Genentech 234
Genentech Enters into Licensing Agreement with PeptiDream for PDPS Technology 235
Galderma Pharma to Enter into Licensing Agreement with Chugai Pharma 236
Genentech Enters into Licensing Agreement with Carmot Therapeutics 237
Roche Enters into Licensing Agreement with Eleven Biotherapeutics 237
Roche Enters into Licensing Agreement with Chugai Pharma for Recycling Antibody SA237 239
Chugai Pharma Enters into Licensing Agreement with Two Cells 240
Roche Enters into Licensing Agreement with Amgen 241
Roche Enters into Licensing Agreement with Blueprint Medicines 241
BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 243
F. Hoffmann-La Roche Enters into Licensing Agreement with Shionogi 243
F. Hoffmann-La Roche Enters into Licensing Agreement with Pieris Pharma 244
F. Hoffmann-La Roche Entered into Licensing Agreement with Proximagen 245
Roche Enters into Licensing Agreement with Cellular Dynamics 246
Genentech Enters into Licensing Agreement with Nimbus Therapeutics 247
Genentech Enters into Licensing Agreement with Arvinas 248
Kowa Company Enters into Licensing Agreement with Chugai Pharmaceutical 249
Genentech Enters into Licensing Agreement with Almac Discovery 249
Roche Enters into Licensing Agreement with Dalcor Pharma 250
Roche Enters into Licensing Agreement with Galenica 251
4D Molecular Therapeutics Enters into Licensing Agreement with Roche 252
Curadev Pharma Enters into Licensing Agreement with Roche 253
Roche Molecular Enters into Licensing Agreement with Qiagen 254
Roche Enters into Licensing Agreement with Meiji Seika Pharma and Fedora Pharma 254
EpiVax Enters into Licensing Agreement with Chugai Pharma 255
NewLink Genetics to Enter into Licensing Agreement with Genentech for NLG919 256
Roche Amends Licensing Agreement with Chugai Pharma 258
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 258
Ark Biosciences Enters into Licensing Agreement with Roche for AK0529 259
Chugai Pharma Enters into Licensing Agreement with Roche 260
Roche Enters Into Licensing Agreement With Prothera 261
Isarna Therapeutics Enters Into Licensing Agreement With Santaris Pharma To Develop Oligonucleotides For TGF-ß-Mediated Diseases 262
Ocera Therapeutics Enters Into Technology Transfer and License Agreement With F. Hoffmann-La Roche 263
Viriom Expands Licensing Agreement With Roche For HIV Treatment 265
Helsinn Enters Into Licensing Agreement With Chugai Pharma Marketing For Anamorelin 266
Heidelberg Pharma Enters Into Licensing Agreement With Roche For Antibody Targeted Amanitin Conjugates 267
Roche To Enter Into Licensing Agreement With Medicines Patent Pool For Saquinavir 268
RaNA Therapeutics Enters Into Licensing Agreement With Santaris Pharma To Develop RNA-Targeted Medicines 268
Immunocore Enters Into Licensing And Research Agreement With Genentech For Cancer Drugs 269
Afraxis Enters Into Licensing Agreement With Genentech 270
Santaris Pharma Expands Licensing Agreement With miRagen Therapeutics For LNA-Drugs 271
Research Ventures & Licensing Enters Into Licensing Agreement With Santaris Pharma 272
Techpool Bio-Pharma Enters Into Licensing Agreement With Roche For Antineoplastic Drug 273
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 274
Dutalys Enters Into Licensing Agreement With Global Pharma Company 275
Curis Enters Into Licensing Agreement With Genentech For IAP Inhibitor CUDC-427 275
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 277
Roche Enters Into Licensing Agreement With Galaxy Biotech For Oncology Program 278
Roche Enters Into Licensing Agreement With Seaside Therapeutics For mGluR5 Antagonists 279
AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies 280
Roche Enters Into Licensing Agreement With Savira Pharma 281
Roche Extends Licensing Agreement With Genedata 283
Lorus Therapeutics Enters Into Licensing Agreement With Genentech For Cancer Drugs 283
Chugai Pharma Extends Licensing Agreement With Genedata For Genedata Expressionist Software 285
Xenon Pharma Extends Licensing Agreement with Genentech 286
Hua Medicine Enters Into Licensing Agreement With Roche For RO5305552 287
Roche Enters Into Licensing Agreement With PTC Therapeutics And SMA Foundation 288
Roche Diagnostics Enters Into Licensing Agreement With Arizona Technology And Columbia University 289
Chugai Pharma Enters Into Licensing Agreement With Roche For MetMAb And Lebrikizumab 290
Chugai Pharma Enters Into Licensing Agreement With Roche For Vemurafenib 291
Synta Pharma Extends Licensing Agreement With Roche 292
FORMA Therapeutics Enters Into Licensing Agreement With Genentech 293
Nycomed Enters Into Licensing Agreement With F. Hoffmann-La Roche For Bonviva 294
Roche Enters Into Licensing Agreement With TeaRx 295
Santaris Pharma Enters Into Licensing Agreement With Massachusetts General Hospital 296
Synta Pharma Extends Its Licensing Agreement With Roche 297
Polyplus-transfection Enters Into Licensing Agreement With Roche Glycart 297
Nerviano Medical Sciences Enters Into Licensing Agreement With Genentech 298
Spirogen Enters Into Licensing Agreement With Genentech 299
AMRI Enters Into Licensing Agreement With Genentech 300
Equity Offering 301
Opsona Therapeutics Raises USD10.58 Million in Private Placement of Shares 301
Foundation Medicine Raises USD250 Million in Private Placement of Shares 302
Ariosa Diagnostics Withdraws IPO 303
Foundation Medicine Withdraws Public Offering Of Shares For Up To US$150 Million 304
InterMune Completes Public Offering Of Shares For US$282.5 Million 305
InterMune Completes Underwriters Exercise Of Over-Allotment Option Of Public Offering Of Shares For US$97.2 Million 306
Foundation Medicine Completes IPO Of Shares For US$122 Million 308
InterMune Completes Public Offering Of Common Stock For US$154 Million 309
InterMune Completes Underwritten Public Offering Of Common Stock For US$110 Million 310
Debt Offering 312
Roche Prices Public Offering of Bonds Due 2020 for USD600 Million 312
Roche Prices Public Offering of 0.875% Bonds Due 2025 for USD1.14 Billion 312
Roche Plans to Raise USD850 Million in Public Offering of Notes 313
Roche Plans to Raise USD500 Million in Public Offering of Bonds 314
Roche Plans to Raise USD1.3 Billion in Public Offering of Bonds Due 2021 315
Roche Plans to Raise USD1.3 Billion in Public Offering of Bonds Due 2024 316
Roche Plans to Raise USD300 Million in Public Offering of Bonds 316
Roche Plans to Raise USD1.5 Billion in Public Offering of Bonds 317
InterMune Completes Public Offering Of Notes Due 2017 For US$137 Million 318
Roche Completes Public Offering Of Bonds Due 2018 For US$658 Million 319
Roche Completes Public Offering Of Bonds Due 2022 For US$548 Million 320
Roche Completes Public Offering Of Bonds Due 2013 For US$438 Million 321
Roche Completes Public Offering Of Bonds Due 2018 For US$1.32 Billion 322
InterMune Completes Public Offering Of Convertible Senior Notes Due 2018 For US$155 Million 323
Asset Transactions 324
Patheon Acquires API Manufacturing Site, South Carolina from Roche 324
F. Hoffmann-La Roche May Sell its Diabetes Care Business 325
Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 326
Atnahs Pharma Acquires Naprosyn, Anaprox and Toradol from Roche 327
Pediapharm Acquires Naproxen Suspension from Roche 328
Amgen Acquires Filgrastim and Pegfilgrastim Rights from Roche for USD479 Million 329
Vidara Therapeutics International Acquires Actimmune From InterMune For US$55 Million 330
RIEMSER Arzneimittel Acquires Worldwide Rights Of Ostac From Roche 332
Arrowhead Research Acquires RNAi Assets From Roche 333
Gilead Sciences Completes Acquisition Of Oceanside Clinical Plant From Genentech For US$28.3 Million 334
Roche Sells Palo Alto Facility 335
Acquisition 335
Roche Acquires ForSight VISION4 from ForSight Labs 335
Novartis Plans to Sell its Stake in F. Hoffmann-La Roche 336
Noritsu Koki to Acquire 64.7% Stake in Genentech for USD27 Million 337
Roche Acquires Tensha Therapeutics 338
Pacific Biosciences May Sell Itself 339
Roche Acquires Kapa Biosystems 340
Roche Acquires Adheron Therapeutics 340
Roche Acquires CAPP Medical 341
Roche Acquires Majority Stake in Foundation Medicine for USD1.03 Billion 342
Roche May Acquire BioMarin Pharma 343
Roche Acquires Trophos for USD386 Million 344
Roche Acquires Signature Diagnostics 346
Roche Acquires InterMune for USD8.3 Billion 347
Roche Acquires Bina Technologies 348
Roche to Acquire Dutalys for USD489 million 349
Tetraphase Pharma May Sell Itself 350
Roche Acquires Santaris Pharma for USD450 Million 351
Roche Completes Acquisition of Seragon Pharma for USD1.72 Billion 352
Roche May Acquire 40% Stake in Chugai Pharma 353
F. Hoffmann-La Roche Completes Acquisition of Iquum for USD450 Million 354
Roche Diagnostics Acquires Genia for up to USD350 Million 355
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 356
Roche Rumored To Acquire BioMarin Pharma For US$13.5 Billion 357
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 358
Takeda Completes Acquisition Of Remaining 87.5% Stake In Envoy Therapeutics For Up To US$140 Million 359
Roche Completes Acquisition Of Anadys Pharma For US$230 Million 361
Roche Holding Plans To Acquire A Pharma Company 362
International Chemical Investors Acquires Roche Colorado 363
Roche Sells Roche Vitamins 364
F. Hoffmann-La Roche Ltd - Key Competitors 365
Key Employees 366
Locations And Subsidiaries 367
Head Office 367
Other Locations & Subsidiaries 367
Recent Developments 379
Financial Announcements 379
Feb 01, 2017: Roche reports good results in 2016 379
Oct 20, 2016: Roche delivers good sales growth in the first nine months of 2016 382
Jul 21, 2016: Roche delivers continued growth in the first half of 2016 385
Apr 19, 2016: Roche reports solid sales growth in the first quarter of 2016 387
Jan 28, 2016: Roche reports strong results in 2015 389
Corporate Communications 393
Dec 05, 2016: Changes in Roche Board of Directors 393
Jan 28, 2016: Changes to the Roche Corporate Executive Committee 394
Legal and Regulatory 395
Jul 04, 2016: Infringement procedure against Roche – EMA update 395
Jul 04, 2016: Sri Lankan Court Dismisses F. Hoffmann-La Roche’s Lawsuit To Ban the Distribution Of Trastuzumab And Bevacizumab produced by BIOCAD 396
Government and Public Interest 397
Jul 29, 2016: Roche comments on new Cancer Drugs Fund 397
Product News 398
12/06/2016: FDA Approves Genentech’s Avastin (Bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer 398
Nov 07, 2016: Roche launches new RNA HyperPrep product line 399
10/27/2016: Roche announces FDA approval for VENTANA PD-L1 (SP142) Assay to support immunotherapy treatment decisions in lung cancer 400
06/29/2016: Cancer Genetics Expands Its Immuno-Oncology Franchise With The Addition of The FDA-Approved Ventana PD-L1 (sp142) Assay As A Complementary Diagnostic Test For TECENTRIQ 401
06/05/2016: New Drug "Retrains" Immune System to Fight Aggressive Bladder Cancer 402
05/23/2016: Anti-Cancer Agent Avastin, Obtained Approval for Additional Indication of Advanced 404
05/19/2016: Aurora Diagnostics to Offer PD-L1 Tissue Assay for TECENTRIQ (atezolizumab) 405
05/19/2016: New Complementary Diagnostic Test Available from LabCorp for Treatment of Bladder Cancer 406
05/18/2016: FDA Grants Genentech’s Cancer Immunotherapy TECENTRIQ (atezolizumab) Accelerated Approval for People with a Specific Type of Advanced Bladder Cancer 407
05/10/2016: Major new global study identifies a safer treatment of acute stroke 408
04/29/2016: CHMP recommends EU approval for Roche’s Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer 409
04/11/2016: Data on ORY-1001 to Be Presented at the AACR Annual Meeting 2016 in New Orleans 410
04/10/2016: FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer 411
03/15/2016: Experimental Targeted Immunotherapy Drug Performs Better Than Chemotherapy for Treatment of Advanced Lung Cancer 412
02/18/2016: Clot-busting therapy reduces mortality in deadliest form of stroke 413
02/17/2016: FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis 415
01/26/2017: First immunotherapy treatment for bladder cancer fast-tracked under UK’s Early Access to Medicines Scheme (EAMS) 416
Product Approvals 417
Feb 17, 2017: New Drug Application Filed for Immune Checkpoint Inhibitor, Atezolizumab - First Application as anti PD-L1 Antibody for the Treatment of Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer in Japan 417
Jan 09, 2017: FDA grants Roche's cancer immunotherapy TECENTRIQ (atezolizumab) Priority Review in additional type of advanced bladder cancer 418
Dec 22, 2016: Avastin Received Orphan Drug Designation for the Treatment of Malignant Pleural Mesothelioma 419
Oct 18, 2016: FDA Approves Genentech’s Cancer Immunotherapy Tecentriq (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer 420
Mar 15, 2016: FDA grants Roche’s Cancer Immunotherapy Atezolizumab priority review for advanced bladder cancer 421
Clinical Trials 422
Feb 17, 2017: Phase II Study Supports Potential for Genentech’s Tecentriq (Atezolizumab) Plus Avastin (Bevacizumab) for People with Locally Advanced or Metastatic Renal Cell Carcinoma 422
Jan 09, 2017: ORYZON Announces First Patient Dosed in Phase 1 Trial of the LSD1 inhibitor RG6016 in Small Cell Lung Cancer (SCLC) 424
Dec 05, 2016: ORYZON Announces Encouraging Top-line Results from Phase I-IIA Clinical Trial in Acute Leukemia of RG6016 (ORY-1001) at the American Society of Hematology 2016 Annual Meeting 425
Nov 14, 2016: ORYZON to Present Clinical Data on LSD1 Inhibitor ORY-1001 at ASH 2016 426
Oct 08, 2016: Genentech’s TECENTRIQ (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy Regardless of PD-L1 Status in a Specific Type of Lung Cancer in Phase III Study 427
Oct 03, 2016: First phase III data on Roche’s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress 428
Aug 31, 2016: Phase III Study Showed Genentech’s Cancer Immunotherapy TECENTRIQ (Atezolizumab) Helped People with a Specific Type of Lung Cancer Live Significantly Longer Compared to Chemotherapy 430
Jun 29, 2016: Anti-PD-L1 immunotherapy responsive in microsatellite-stable mCRC comb with MEK inhibition 431
Jun 08, 2016: Roche receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer 432
Jun 05, 2016: Roche's cancer immunotherapy Tecentriq (atezolizumab) shrank tumours in people with previously untreated advanced bladder cancer 434
May 02, 2016: Study Proves Long-Term Effectiveness of Avastin for Treating Major Cause of Blindness 436
Jan 08, 2016: Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer 437
Other Significant Developments 438
Nov 14, 2016: Roche launches imCORE, a global network of cancer immunotherapy centers of excellence 438
May 06, 2016: Roche Announces Direct Sales of Kapa Biosystems NGS Products in Canada 439
Appendix 441
Methodology 441
About GlobalData 441
Contact Us 441
Disclaimer 441List of Tables
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 1
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 19
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 20
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 21
F. Hoffmann-La Roche Ltd, Deals By Therapy Area, 2011 to YTD 2017 22
F. Hoffmann-La Roche Ltd, Medical Devices Deals, 2011 to YTD 2017 24
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 25
Roche to Acquire Heat Elution Purification Technology from Lumora 51
Roche Acquires PETE Technology from AbVitro 51
Genentech Acquires NanoPrint LM60 Microarrayer Platform From Arrayit 52
Roche To Acquire Gene Sequencing Technologies From Three Universities 53
SutroVax Raises USD64 Million in Series B Financing 54
Tioma Therapeutics Raises USD86 Million in Series A Financing 55
Second Genome Raises USD8.4 Million in Extended Series B Financing 56
Second Genome Raises USD42.6 Million in Series B Financing 57
Lumos Pharma Raises USD34 Million in Series B Financing Round 59
Mission Therapeutics Raises USD85.7 Million in Financing Round 60
Biodesy Raises USD10 Million in Series B Financing 62
C4 Therapeutics Raises USD73 Million in Series A Financing Round 63
Millendo Therapeutics Raises USD62 Million in Series B Venture Financing 64
Minoryx Therapeutics Raises USD22 Million in Series A Financing Round 65
Corvus Pharma Raises USD75 Million in Series B Venture Financing 67
AveXis Raises USD65 Million in Venture Financing 68
SutroVax Raises USD22 Million in Series A Venture Financing 70
Stratos Genomics Raises Additional USD15 Million in Series B Financing 71
Allakos Secures USD27.95 Million in Venture Funding 72
Macrolide Pharma Raises USD22 Million in Series A Financing 73
Lysosomal Therapeutics Raises USD20 Million in Series A Financing 74
AveXis Raises USD10 Million in Series C Financing Round 75
CytomX Therapeutics Raises USD20 Million in Series C Venture Financing 76
Curetis Raises USD18 Million in Extended Series B Venture Financing 77
Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 79
Allakos Raises USD10 Million in Extended Series A Venture Financing 81
Epic Sciences Raises USD30 Mi
